< BACK Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Feb 5, 2026 New iPROLEPSIS publication presents a smartphone-based approach for remote joint swelling assessment in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . The study investigates the use of smartphone photographs to support the remote assessment of swollen joints in patients with inflammatory arthritis, focusing on psoriatic arthritis. The proposed method classifies each interphalangeal joint in hand photographs as swollen or not swollen, supporting scalable and patient-friendly monitoring approaches. Read the full publication: https://zenodo.org/records/18481583 iPROLEPSIS_Apostolidis G._HealthCom.png iPROLEPSIS_Apostolidis G._HealthCom.png 1/1 PREVIOUS NEXT

< BACK Hot topic debate: preventing psoriatic arthritis in patients with psoriasis Nov 13, 2024 Preventing PsA: Insights from the IFPA-WPPA 2024 Conference Conference IFPA-WPPA 2024 Conference At the 7th World Psoriasis & Psoriatic Arthritis (IFPA-WPPA) Conference , experts discussed whether effective treatment for psoriasis (PsO) could help prevent the onset of psoriatic arthritis (PsA). In this session, Prof. Laura Coates highlighted early intervention as a key strategy for PsA prevention. Supporting these efforts, the iPROLEPSIS consortium, active across Europe, is exploring digital, non-pharmacological tools aimed at improving patient outcomes. These include stress management games designed to offer additional support for people with PsO, focusing on prevention beyond medications alone. Alongside iPROLEPSIS, other studies, including the PAMPA study and HIPPOCRATES Prospective Observational Study (HPOS), are investigating early detection and intervention strategies. Digital tools such as the Psorcast app, along with new apps from iPROLEPSIS, are being developed to monitor psoriasis patients for early signs of PsA. These efforts aim to pave the way for more personalised and preventive care approaches. Abstract Can effective treatment of psoriasis (PsO) prevent the development of psoriatic arthritis (PsA)? In a Hot Topic Debate at the 7th World Psoriasis & Psoriatic Arthritis Conference, Dr. Soriano and Dr. Ogdie, both experts in the field, presented contrasting views based on existing research and clinical studies.1 Dr. Soriano argued that biologic treatments for PsO may reduce PsA risk, citing several retrospective studies. On the other hand, Dr. Ogdie argued that current observational data are plagued by biases, making it difficult to conclude whether biologics play a protective role. The session outlined the complexity of this issue, with both speakers agreeing on the need for prospective randomised controlled trials, such as the ongoing PAMPA study, to provide definitive answers. Prof. Laura Coates added that identifying at-risk patients and intervening early to potentially prevent PsA may point to a strategic research approach to address these unanswered questions. Read the full article: https://conferences.medicom-publishers.com/proceedings/proceedings-in-dermatology/7th-ifpa-wppa-conference/preventing-psoriatic-arthritis-in-patients-with-psoriasis/ 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the MULTIPULM project kick-off meeting Oct 8, 2025 iPROLEPSIS tools to be adapted for clinical studies in Brazil, Serbia, and Türkiye The iPROLEPSIS project was presented during the kick-off meeting of the MULTIPULM project, held on 29–30 September in Athens. iPROLEPSIS partners Aristotle University of Thessaloniki (AUTH) , Faculdade de Motricidade Humana (FMH) , and Wellics participated in the meeting, which brought together researchers, clinicians, user research experts, and technology providers. Several tools developed within iPROLEPSIS – including the breathing games created by FMH and the biAURA app developed by AUTH – will be further used in MULTIPULM. These tools will be adapted to the local needs of the project’s pilot sites in Brazil, Serbia, and Türkiye, and evaluated in relevant clinical studies. This collaboration demonstrates the adaptability and broader potential of iPROLEPSIS digital tools beyond psoriatic arthritis, supporting research in other chronic conditions. SPBTU_KoM_MULTIPULM_Athens.jpg ae74e3_e25adf83abf6411cace29ed99801554f~mv2.jpg SPBTU_KoM_MULTIPULM_Athens.jpg 1/2 PREVIOUS NEXT

< BACK Psoriatic Arthritis Awareness Day Sep 28, 2023 iPROLEPSIS project is joining to celebrate the Psoriatic Arthritis Awareness Day This September 28th, the iPROLEPSIS project is joining to celebrate Psoriatic Arthritis Awareness Day, dedicated to raising awareness of the painful inflammatory disease often linked with psoriasis. iPROLEPSIS is a research and innovation initiative. The project uses cutting-edge technology and AI to develop a novel personalised digital care ecosystem for people with Psoriatic Arthritis. Join us on September 28th and help reshape the future of Psoriatic Arthritis care! https://video.wixstatic.com/video/981fae_b35edf1e5e4144c786e814aec1d1a28f/1080p/mp4/file.mp4 News & Events iPROLEPSIS - events.png News & Events iPROLEPSIS - events.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS 3rd Plenary meeting successfully closed Dec 14, 2023 Navigating Progress: Highlights from the 3rd iPROLEPSIS Plenary Meeting in Rotterdam On 12-13 December 2023 , the iPROLEPSIS consortium gathered for the 3rd plenary meeting in Rotterdam, the Netherlands. The agenda included: Four workshops External Advisory Board session Clinical studies overview, including PDPID study, Mast cells and optoacoustic-enabled joint and microvascular imaging (iPROLEPSIS-MOJMI) study, HPOS, and iPROLEPSIS integration General assembly session Overview of work packages with progress updates Strategic planning for the next steps. Four productive workshops were held: 1️⃣ PDPID study deployment and app: Ethical approval timeline SOP and OpenOpenClinica / eCRF App and cloud backend status UI/UX and translation timeline Usability testing 2️ ⃣ Digital biomarkers and data fusion Data retrieval roadmap Analysis methodologies Data fusion/modelling methodology MLOps solutions iPROLEPSIS-MOJMI-relevant biomarkers extraction 3️ ⃣ Technical workshop on digital ecosystem development Open issues and data collection monitoring Technical monitoring and orchestration needs MLOps technical aspects Alpha version of the digital ecosystem 4️ ⃣ Serious games co-creation session with patient partners Game design Stakeholders’ feedback We are grateful to patient representatives who joined the cocreation session . Their valuable input and perspectives are crucial for understanding the specific needs and requirements of those who will benefit from the iPROLEPSIS project. By actively involving patient representatives , we can ensure our solutions are patient-centric and tailored to their experiences and challenges. Thank you to Erasmus University Rotterdam for hosting the event. DSC03942.JPG IMG_7110.jpg iPROLEPSIS_cookies.JPG DSC03942.JPG 1/7 PREVIOUS NEXT

< BACK iPROLEPSIS 8th Plenary Meeting in Athens Jun 10, 2026 Partners met to review progress and align on next steps The iPROLEPSIS consortium held its 8th Plenary Meeting on 8–9 June 2026 in Athens, Greece, hosted by project partners DBC and Ainigma Technologies. Partners reviewed the project's latest progress and aligned on priorities for the coming months. Over two days, the consortium discussed updates across all active areas of the project – from data harmonisation and predictive modelling to clinical study status, platform development, and dissemination and communication activities. Progress on exploitation and regulatory planning was also presented. An External Advisory Board (EAB) session was held, where board members reviewed key project results and provided scientific and strategic feedback. The plenary concluded with a summary of agreed actions and priorities. Partners will focus on advancing the clinical studies, continuing development of the iPROLEPSIS ecosystem, progressing scientific work on digital biomarkers and predictive models, and delivering the next planned milestones and deliverables. 1.1.jpg 20260608_104240.jpg 20260608_104203.jpg 1.1.jpg 1/4 PREVIOUS NEXT

< BACK DHU extends Call for Twinnings Deadline until October 13! Sep 20, 2023 DigitalHealthUptake (DHU) project has extended the submission deadline of the twinning applications In a move that promises to fuel innovation and support the acceleration of digital health initiatives, we are thrilled to announce that our synergy partner project, the DigitalHealthUptake (DHU) project, has extended the submission deadline of the twinning applications until October 13, 2023. Why apply for the DHU Call for Twinnings? Participating in the DHU Call for Twinnings offers a multitude of advantages: Knowledge Exchange: Engage in fruitful knowledge sharing with fellow innovators, gaining fresh insights and perspectives. Access to Innovative Solutions: Unlock the door to cutting-edge digital health solutions that can revolutionise healthcare in Europe. Networking Opportunities: Connect with a diverse and influential network of industry experts, thought leaders, and change-makers. Funding for Transformation: Access financial support to implement transformative digital applications, accelerating progress and impact in the health and care domain. What types of twinnings are being funded? Citizen/patient-focused twinning topics: Digital tools to support health education (health literacy), digital health literacy mHealth systems, wearable devices for monitoring and prevention, alerts, reminders Digital tools to support patient feedback and reporting of outcomes and experiences Digital tools to support proactive prevention, self-management, homecare, telemonitoring Tele-mentoring/coaching, virtual consultations, virtual coach, personal assistant ICT supporting adherence to medication and care plans Robotics (e.g., companion robots) Use of digital therapeutics Tools and services supporting independent living, ambient assisted living technologies, telecare Care practitioner-focused twinning topics: Advanced digital tools to support Integrated Care, including integration of health and social care services Interoperable digital solutions to support person-centred and integrated care Regional and national Electronic Health Record (EHR) systems and ePrescription solutions enabling person-centred care Regional, national and local Electronic Integrated Care Record (EICR) systems, integration of EHR and social care records Digital shared care plans (e.g., support to multi-disciplinary team(s)) Decision support for multi-morbidity and polypharmacy management ICT support for management of frailty ICT support for falls prevention eLearning to support workforce development for person-centred integrated care Important links Ready to take the next step? Here are some crucial links you'll need: How to apply: Access the application form here . Q&A document: Got questions? Check our Q&A document for answers. Webinar recording: Missed our informative webinar on the call? No problem! You can watch the recording here. Don't miss out on this opportunity to accelerate digital health solutions in Europe. Apply now! News & Events iPROLEPSIS - events.png News & Events iPROLEPSIS - events.png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search What causes psoriatic arthritis? See related Handbook section PREVIOUS NEXT

< BACK Transforming Psoriatic Disease Care Through Innovation and Real-World Data: GRAPPA 2025 Soapbox Highlights May 18, 2026 The article highlights how iPROLEPSIS uses digital tools, smartphone-based data and explainable AI to support personalised psoriatic arthritis monitoring The iPROLEPSIS project has been featured in a newly published article in The Journal of Rheumatology , based on highlights from the GRAPPA 2025 Annual Meeting , held in Bogotá, Colombia. During the meeting, Dr. Vasileios Charisis presented the iPROLEPSIS approach to psoriatic arthritis monitoring. The project applies digital phenotyping and explainable artificial intelligence to analyse smartphone-based data, including typing dynamics and hand motion tracking. The article describes how these digital tools may help detect functional impairments related to psoriatic arthritis. Pilot data showed promising accuracy, supporting the potential of digital biomarkers for more personalised disease monitoring and management. Read the full paper: https://www.jrheum.org/content/early/2026/05/10/jrheum.2026-0371 jrheum.2026-0371.full .pdf Download PDF • 724KB 1/0 PREVIOUS NEXT

< BACK iPROLEPSIS patient survey Jun 26, 2023 iPROLEPSIS patient survey launched Have you been diagnosed with Psoriatic Arthritis ? Then we would love to get your opinion! 👉 The upcoming 4 years our European Research Team will dedicate itself to the iPROLEPSIS project. Within this project we will develop Digital Health Tools that can help you monitor your condition and can aid in the management of your Psoriatic Arthritis by providing personalised recommendations 🚀 This research was initiated by many conversations with people with Psoriatic Arthritis , who stated that the process of Trial and Error with regard to finding balance in life and gaining control over this condition is very long and complicated. We kindly ask you to complete our survey about the Digital Health Tools to be developed. This way we can design them as is important for you! 👉 The survey is available in 4 different languages available through the following links: 🔗 English: https://lnkd.in/eMhFEHMX 🔗 Greek: https://lnkd.in/en3cs-bV 🔗 Portuguese: https://lnkd.in/dy76S8Rg 🔗 Dutch: https://lnkd.in/ecTgfJh9 Your participation and feedback are valuable to us 👋 Together, we can shape the future of Psoriatic Arthritis management! For further information or if you have any questions, please visit: 🌐 Website: www.iprolepsis.eu 👍 LinkedIn: https://lnkd.in/dnrTP8rC 🐦 Twitter: https://twitter.com/iprolepsis Thank you in advance for contributing your opinion. Your voice matters! News & Events iPROLEPSIS - events.png News & Events iPROLEPSIS - events.png 1/1 PREVIOUS NEXT

< BACK Patty de Groot Discusses Digital Biomarkers in Rheumatology Podcast Jan 10, 2025 Exploring the Future of Digital Biomarkers in Rheumatology Patty de Groot from Erasmus MC recently appeared on the Digital Rheumatology Network podcast on Spotify, where she shared her insights on the role of digital biomarkers in rheumatology care. In this engaging conversation, Patty discusses the potential of digital tools, including findings from the iPROLEPSIS project, to improve early diagnosis, personalise treatment, and enhance patient care. She also talks about the use of design-thinking approaches to optimise healthcare workflows and the challenges of integrating digital innovations in clinical practice. Listen to the full podcast episode to learn more about how digital biomarkers are transforming rheumatology care and the future of healthcare innovation. 🎧 Listen here 1/1 PREVIOUS NEXT

< BACK Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers Oct 30, 2024 The qualitative study exploring the perspective of psoriatic arthritis (PsA) patients towards the digital biomarkers (dBMs) Latest research initiative under the iPROLEPSIS project: Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers Abstract Objectives The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Methods As part of a Design Thinking approach, six focus groups were conducted involving 27 PsA patients. The semistructured topic guide included disease activity, coping strategies, care needs, and potential advantages and disadvantages of dBMs. Thematic analysis followed an abductive coding method. Results PsA daily permeates patients’ lives, both physically and mentally. Participants discussed how their lives are focused on minimising the impact of the disease on their daily routines. Their attempts to gain control over their disease highly depend on trial and error. Flare-ups are related to physiological as well as behavioural micro and macro changes. Understanding these changes could enable the detection of (early) flare. Participants elicited pros and cons of the use of dBMs, discussed their intended use and made practical remarks. This led to three main themes: ‘Perceived dBM opportunities’, ‘Mapping Disease activity’ and ‘Perceived dBM barriers and pitfalls’. Conclusion PsA patients are receptive to dBMs for tracking the disease symptoms. Disease activity is regarded multifaceted and thus, dBMs should include a broad range of features to truly reflect the disease activity status. Reducing the time of trial and error in learning to manage the disease is regarded beneficial. Establishing and maintaining the relationship with their attending physicians is a prerequisite, even if remote patient monitoring becomes an alternative for some physical hospital visits. Read the full publication in RMD Open: https://rmdopen.bmj.com/content/10/4/e004699 Digital biomarkers for psoriatic arthritis a qualitative focus groups study on patient-per .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT